ARISTADA aripiprazole lauroxil Updated Nov 4
ARISTADA is a mature commercial asset with no upcoming binary catalyst; the stock's next major value inflection points are the orexin pipeline readouts (alixorexton Phase 3 narcolepsy data expected mid-2027). Watch ARISTADA's quarterly sales trajectory for competitive erosion signals from newer LAIs like UZEDY and Invega Hafyera, but the drug's patent protection through 2039 limits near-term generic risk.
- ARISTADA is a well-established, FDA-approved long-acting injectable for schizophrenia with flexible dosing (monthly, 6-week, and 2-month options), offering convenience that supports adherence vs daily oral antipsychotics.
- Patent protection extends to approximately April 2039, providing a long runway of exclusivity with no near-term generic threat.
- The ALPINE Phase 3b study demonstrated ARISTADA's efficacy was comparable to Invega Sustenna, providing physicians with head-to-head data to support prescribing decisions.
- ARISTADA net sales declined slightly year-over-year in Q2 2026 ($96.7M vs $101.3M), signaling competitive pressure in the LAI antipsychotic market from J&J's Invega Sustenna/Trinza/Hafyera, Otsuka's Abilify Maintena, and newer entrants like UZEDY.
- Patent expiry is distant (2039) but the drug faces a mature, increasingly crowded market where differentiation is difficult; the ALPINE trial showed comparable (not superior) efficacy to Invega Sustenna.
- Alkermes' Q3 2026 GAAP net income fell to $16.3M from $87.1M a year earlier due to higher R&D and SG&A costs from the Avadel acquisition and pipeline investment, pressuring near-term profitability.